Facet-Dependent Biodegradable Mn<sub>3</sub> O<sub>4</sub> Nanoparticles for Ameliorating Parkinson's Disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34601811.
- Also identified by DOI 10.1002/adhm.202101316.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Parkinson's disease (PD) is a common neurodegeneration disease. Unfortunately, there are no effective measures to prevent or inhibit this disease. In this study, biodegradable Mn<sub>3</sub> O<sub>4</sub> nanoparticles (NPs) in different shapes are prepared and enclosed them by {100}, {200} and {103} facets that exhibit facet-dependent protection against neurotoxicity induced by oxidative damage in a cell model of PD. Notably, Mn<sub>3</sub> O<sub>4</sub> nanorods enclosed by {103} facets exhibit high levels of enzyme-like activity to eliminate reactive oxygen specie in vitro. It is also determined that the uptake pathway of Mn<sub>3</sub> O<sub>4</sub> NPs into MN9D cells is mediated by caveolin. The data demonstrate that Mn<sub>3</sub> O<sub>4</sub> nanorods can be taken up by cells effectively and confer excellent levels of neuroprotection while the biodegradation of Mn<sub>3</sub> O<sub>4</sub> NPs in vivo is confirmed by photoacoustic image of Mn<sub>3</sub> O<sub>4</sub> NPs in brain at 60 d. Furthermore, the oxygen scavenging effect created by Mn<sub>3</sub> O<sub>4</sub> nanorods is successfully applied to a mouse model of PD; the amount of α-synuclein in the cerebrospinal fluid of PD mice is reduced by 61.2% in two weeks, thus demonstrating the potential application of facet-directed Mn<sub>3</sub> O<sub>4</sub> NPs for the clinical therapy of neurodegenerative disease.
Medical subject headings
- Nanoparticles
- Neurodegenerative Diseases
- Parkinson Disease